Chief Commercial Officer
CurrentFull P&L responsibility for US assets in Human Health and Animal Health divisions. Provided board-level executive leadership regarding short and long-term strategic planning and execution. Key Achievements• Successfully turned around an inline retail channel asset to specialty pharmacy distribution and implemented a suite of patient support programs that improved medication access. GTN increased from ~30% to ~75% over a two-year transition period. Most recent year-over-year net sales increased by 112% for a 10-year-old drug with flat spending. Gross profit increased by 8x from 2019 to 2022.• Achieved operating profitability in 2021 for the commercial team for the first time in the company’s history.• Led launch planning and market-shaping activities for a chloride ion channel modulator in the Oncology supportive care market.• Launched a first-in-class chloride ion channel modulator in the veterinary Oncology market.• Supported a variety of BD efforts that resulted in two ex-US licensing deals for commercial assets.